
Companion Diagnostics: Technologies and Markets
Description
Companion Diagnostics: Technologies and Markets
Report Scope
The current report provides detailed coverage of the companion diagnostics market. This report highlights the current and future market potential of companion diagnostics, and it includes a detailed analysis of the drivers, opportunities, restraints, and challenges in the market. The report details the companion diagnostics market share based on product and service, type of test, technology, and application. The market’s products and services is segmented into instruments, consumables, and services. It is categorized based on the type of test into commercial CDx and lab-developed tests (LDT)-CDx. Based on technology, the market is segmented into polymerase chain reaction, immunohistochemistry, next-generation sequencing, in situ hybridization, genotyping, immunoassays, exosomes, others, and services market. Based on application, the CDx market is categorized into cancer, neurologic disorders, cardiovascular disease, infectious disease, and others. Based on end users, the companion diagnostics market is segmented into clinical laboratories, pharmaceutical companies, contract research organizations (CROs), and other end users. The report also includes company profiles of the major players in the companion diagnostics market, with details about each company's business segments, financials, product portfolios, and recent developments.
By geographical region, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The North America region includes the U.S. and Canada; Europe includes Germany, the U.K., Italy, France, and the Rest of Europe; Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2020 and 2021 as the historic years, 2022 as the base year, and 2028 as the forecast year.
Report Includes
54 data tables and 59 additional tables
Overview and an analysis of the global markets for companion diagnostics (CDx).
Analyses of the global market trends, with historical market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028.
A look at the current and future market potential of companion diagnostics along with the market dynamics, competitive landscape and regulatory scenario.
Estimate of the market size and revenue forecast for the global CDx market, and corresponding market share analysis based on product and services, test type, technology, application, end user and region.
Discussion of the market opportunities for CDx products by identification of high-growth applications in different therapeutic areas, with a focus on the largest and fastest-expanding markets for diseases.
Analysis of recent market developments and clinical trials, as well as the leading companies engaged in R&D and product developments in CDx reagents.
Discussion of the importance of ESG in the CDx industry, including consumer attitudes, the impact of ESG on company performance, ESG score analysis, and ESG practices followed by leading companies.
Review of key patent grants and patent applications related to CDx.
Identification of the major vendors along with an analysis of the competitive intelligence, including companies’ market shares, recent M&A activity, and venture funding outlook.
Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., and QIAGEN
Companies Mentioned
ABBOTT
AGILENT TECHNOLOGIES INC.
ARUP LABORATORIES
BIOMERIEUX
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
ILLUMINA INC.
MYRIAD GENETICS INC.
QIAGEN
THERMO FISHER SCIENTIFIC INC.
Table of Contents
121 Pages
- Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Highlights of the Market for Companion Diagnostics (CDx)
- Chapter 2 Market Overview
- Introduction
- History
- Regulatory Landscape
- Companion Diagnostics Regulations in the U.S.
- Companion Diagnostics Regulations Outside the U.S.
- LDT-CDx Regulation
- Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Market Challenges
- Chapter 4 Emerging Technologies and Developments
- Emerging Technologies
- Multiplex Testing
- Next-Generation Sequencing (NGS)
- Digital PCR
- Liquid Biopsy
- Artificial Intelligence
- Chapter 5 Market Segmentation Analysis
- Segmental Breakdown
- Global Market for Companion Diagnostics by Product and Service
- Market Share and Forecast
- Instruments
- Consumables
- Services
- Global Market for Companion Diagnostics by Type of Test
- Market Share and Forecast
- LDT-CDx
- Commercial CDx
- Global Market for Companion Diagnostics by Technology
- Market Share and Forecast
- Polymerase Chain Reaction
- Immunohistochemistry
- Next-Generation Sequencing
- In Situ Hybridization
- Genotyping
- Immunoassays
- Exosomes
- Others
- Services
- Global Market for Companion Diagnostics by Application
- Market Share and Forecast
- Cancer
- Market for the Application of CDx in Cancer by Type
- Neurologic Disorders
- Cardiovascular Disease
- Infectious Diseases
- Other Diseases
- Market Breakdown by End User
- Market Share and Forecast
- Clinical Laboratories
- Pharmaceutical Companies
- Contract Research Organizations (CROs)
- Other End Users
- Geographic Breakdown
- Global Market for Companion Diagnostics by Region
- North America
- The U.S.
- Canada
- Europe
- Germany
- The U.K.
- France
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
- Rest of the World
- Chapter 6 Competitive Intelligence
- Market Share Analysis
- Leading Market Players in Companion Diagnostics Market, by Technology
- Grants and Funding in Companion Diagnostics
- Recent Developments of Key Market Players
- Clinical Trials Analysis
- Clinical Trials Analysis, by Type of Study
- Clinical Trials Analysis, by Status
- Clinical Trials Analysis, by Phase
- Clinical Trials Analysis, by Region
- Patent Analysis
- Patents, by Year
- Patents, by Top Applicant
- Patents, by Top Owner
- Patents, by Jurisdiction
- Chapter 7 Sustainability in Companion Diagnostics: ESG Perspective
- Introduction to ESG
- Sustainability in the Companion Diagnostics Industry: An ESG Perspective
- Key ESG Issues
- Concluding Remarks from BCC
- Chapter 8 Appendix
- Methodology
- References
- Company Profiles
- ABBOTT
- AGILENT TECHNOLOGIES INC.
- ARUP LABORATORIES
- BIOMERIEUX
- DANAHER CORP.
- F. HOFFMANN-LA ROCHE LTD.
- ILLUMINA INC.
- MYRIAD GENETICS INC.
- QIAGEN
- THERMO FISHER SCIENTIFIC INC.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.